FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.

Background: ) participates in tumor resistance by playing the function of homologous recombination repair(HRR). However, the role of in non-small cell lung cancer (NSCLC) is still unclear. This study aims to understand the expression of in NSCLC and preliminarily explore its relationship with cisplatin resistance.

Methods: messenger RNA (mRNA) was analyzed in 1018 NSCLC tissues and 111 adjacent tissues using The Cancer Genome Atlas program. mRNA in cisplatin-resistant and cisplatin-sensitive cell lines was analyzed by the Gene Expression Omnibus project. FIGNL1 protein was detected in 58 NSCLC tissues and 58 adjacent tissues by immunohistochemistry. The relationship between FIGNL1, clinical pathological characteristics and disease-free survival was retrospectively analyzed. Gene ontology was used to analyze the biological process mainly involving , and STRING online constructed its protein interaction network and screened the key genes (hub genes).

Results: The Cancer Genome Atlas showed that mRNA was higher in 1018 NSCLC tissues than in 111 adjacent tissues ( < 0.05). In the dataset "GSE157692," mRNA was higher in cisplatin-resistant cell lines ( = 3.80e-05). The hub genes in and HRR directions are and . Immunohistochemistry showed that the FIGNL1 protein in 58 NSCLC tissues was higher than that in 58 adjacent tissues ( < 0.01). FIGNL1 is associated with gender, histopathological type, and nerve invasion in NSCLC. The disease-free survival in NSCLC patients with high FIGNL1 expression was shorter ( = 0.032).

Conclusion: FIGNL1 is associated with poor prognosis in NSCLC, and cisplatin resistance may be involved. These observations provide a clinical basis for exploring FIGNL1 as a potential biomarker for cisplatin resistance in NSCLC.